See more : Berentzen-Gruppe Aktiengesellschaft (BEZ.DE) Income Statement Analysis – Financial Results
Complete financial analysis of MaxCyte, Inc. (MXCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MaxCyte, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Three Squirrels Inc. (300783.SZ) Income Statement Analysis – Financial Results
- Ion Exchange (India) Limited (IONEXCHANG.NS) Income Statement Analysis – Financial Results
- Adeshwar Meditex Limited (ADESHWAR.BO) Income Statement Analysis – Financial Results
- AirNet Technology Inc. (ANTE) Income Statement Analysis – Financial Results
- Solvar Limited (SVR.AX) Income Statement Analysis – Financial Results
MaxCyte, Inc. (MXCT)
About MaxCyte, Inc.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.29M | 44.26M | 33.89M | 26.17M | 21.62M | 16.67M | 13.99M | 12.27M | 9.29M | 7.16M | 6.81M | 5.06M |
| Cost of Revenue | 4.74M | 5.10M | 3.65M | 2.77M | 2.50M | 1.84M | 1.45M | 1.31M | 1.03M | 957.50K | 808.60K | 830.40K |
| Gross Profit | 36.55M | 39.16M | 30.25M | 23.40M | 19.12M | 14.83M | 12.53M | 10.96M | 8.26M | 6.21M | 6.00M | 4.23M |
| Gross Profit Ratio | 88.51% | 88.48% | 89.24% | 89.43% | 88.44% | 88.96% | 89.61% | 89.34% | 88.89% | 86.64% | 88.12% | 83.59% |
| Research & Development | 23.82M | 19.51M | 15.41M | 17.74M | 17.60M | 11.24M | 11.28M | 4.70M | 3.01M | 2.49M | 2.22M | 2.21M |
| General & Administrative | 30.07M | 25.83M | 18.68M | 8.39M | 6.09M | 5.28M | 4.52M | 4.20M | 2.67M | 2.47M | 2.21M | 2.02M |
| Selling & Marketing | 26.98M | 18.65M | 13.00M | 8.33M | 7.85M | 6.72M | 6.02M | 4.78M | 3.34M | 2.52M | 2.37M | 1.96M |
| SG&A | 57.04M | 44.48M | 31.68M | 16.71M | 13.94M | 12.01M | 10.54M | 8.99M | 6.01M | 4.99M | 4.59M | 3.98M |
| Other Expenses | 3.99M | 2.53M | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 15.70K | 20.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 84.85M | 66.52M | 48.44M | 34.46M | 31.54M | 23.25M | 21.82M | 13.69M | 9.02M | 7.48M | 6.80M | 6.19M |
| Cost & Expenses | 89.59M | 71.62M | 52.08M | 37.23M | 34.04M | 25.09M | 23.28M | 14.99M | 10.05M | 8.44M | 7.61M | 7.02M |
| Interest Income | 10.38M | 3.92M | 150.80K | 65.90K | 206.10K | 170.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.80K |
| Interest Expense | 0.00 | 126.90K | 1.04M | 825.60K | 681.10K | 614.60K | 625.30K | 637.80K | 704.40K | 561.30K | 153.50K | 61.70K |
| Depreciation & Amortization | 4.17M | 2.70M | 1.42M | 1.05M | 613.50K | 344.00K | 142.90K | 105.70K | 93.30K | 92.00K | 116.40K | 115.20K |
| EBITDA | -44.13M | -20.87M | -16.76M | -9.94M | -11.60M | -7.91M | -9.15M | -2.60M | -647.80K | -1.18M | -688.30K | -1.81M |
| EBITDA Ratio | -106.88% | -46.87% | -49.02% | -38.00% | -53.65% | -47.46% | -65.42% | -21.21% | -6.97% | -16.52% | -10.11% | -35.80% |
| Operating Income | -48.30M | -27.36M | -18.19M | -11.06M | -12.42M | -8.42M | -9.29M | -2.72M | -761.10K | -1.28M | -804.70K | -1.96M |
| Operating Income Ratio | -116.98% | -61.82% | -53.66% | -42.25% | -57.44% | -50.55% | -66.44% | -22.20% | -8.19% | -17.81% | -11.83% | -38.79% |
| Total Other Income/Expenses | 10.38M | 3.79M | -893.60K | -759.70K | -475.00K | -444.30K | -625.30K | -622.10K | -684.40K | -561.30K | -153.50K | -25.90K |
| Income Before Tax | -37.92M | -23.57M | -19.08M | -11.82M | -12.90M | -8.87M | -9.92M | -3.35M | -1.45M | -1.84M | -958.20K | -1.99M |
| Income Before Tax Ratio | -91.85% | -53.25% | -56.30% | -45.15% | -59.64% | -53.21% | -70.91% | -27.27% | -15.56% | -25.64% | -14.08% | -39.30% |
| Income Tax Expense | 0.00 | -3.79M | 1.04M | 825.60K | 681.10K | 170.30K | 0.00 | 653.50K | 724.40K | 0.00 | 0.00 | 35.80K |
| Net Income | -37.92M | -19.78M | -20.13M | -12.64M | -13.58M | -8.87M | -9.92M | -3.35M | -1.45M | -1.84M | -958.20K | -1.99M |
| Net Income Ratio | -91.85% | -44.69% | -59.38% | -48.31% | -62.79% | -53.21% | -70.91% | -27.27% | -15.56% | -25.64% | -14.08% | -39.30% |
| EPS | -0.37 | -0.19 | -0.22 | -0.18 | -0.24 | -0.17 | -0.20 | -0.10 | -0.03 | -0.04 | -0.02 | -0.05 |
| EPS Diluted | -0.37 | -0.19 | -0.22 | -0.18 | -0.24 | -0.17 | -0.20 | -0.10 | -0.03 | -0.04 | -0.02 | -0.05 |
| Weighted Avg Shares Out | 103.27M | 101.70M | 90.62M | 69.46M | 56.40M | 51.18M | 48.64M | 33.52M | 43.47M | 43.47M | 43.47M | 43.47M |
| Weighted Avg Shares Out (Dil) | 103.27M | 101.70M | 90.62M | 69.46M | 56.40M | 51.18M | 48.64M | 33.52M | 43.47M | 43.47M | 43.47M | 43.47M |
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte
MaxCyte May Benefit From Potential Gene Therapy Approval
MaxCyte is a pick-and-shovel play on cell editing technology, but may capture a royalty stream from successful products. Vertex's potential candidate approval in the U.S. could prove a decisive catalyst ultimately validating MaxCyte's approach and business model. If MaxCyte's partners...
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines
MaxCyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Sean Menarguez - Head of IR Doug Doerfler - President & CEO Douglas Swirsky - CFO Conference Call Participants Dan Arias - Stiefel...
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance ROCKVILLE, MD, November 8, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
ROCKVILLE, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced...
MaxCyte to Participate in Two Upcoming Investor Conferences
MaxCyte to Participate in Two Upcoming Investor Conferences Rockville, MD, November 6, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics...
MaxCyte to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced...
Penny Stocks To Buy This Week? Analysts Like These 3
Penny stocks are shares of small companies priced under $5 per share. While the potential returns can be alluring, penny stocks carry high risk.
Why Shares of MaxCyte Are Plummeting on Thursday
MaxCyte focuses on cell-engineering platform technology. The company blamed lower orders for a likely revenue decline in the third quarter.
Source: https://incomestatements.info
Category: Stock Reports